Ad hoc-Mitteilungen

Lonza Delivers Strong 2021 performance with 20% CER Sales Growth

| Aufrufe: 255

Lonza Group AG / Key word(s): Annual Results Lonza Delivers Strong 2021 performance with 20% CER Sales Growth 26-Jan-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.


Ad Hoc Release Pursuant to Art. 53 Listing Rules

  • Lonza delivers CHF 5.4 billion sales and 20% CER1 sales growth 
  • CHF 1.7 billion CORE EBITDA resulted in a margin of 30.8% 
  • 2021 CAPEX reached 24% of sales, supporting long-term plan to deliver attractive margins through de-risked growth investments 
  • Continuing focus on operational excellence and execution of growth projects 
  • Outlook 2022: low to mid-teens CER sales growth and CORE EBITDA margin improvement in line with 2024 Mid-Term Guidance 
  • Mid-Term Guidance 2024 reconfirmed
Basel, Switzerland, 26 January 2022 - Lonza has reported sales of CHF 5.4 billion, growing 20% AER (20% CER) and CHF 1.7 billion CORE EBITDA, resulting in a margin of 30.8%. This strong momentum at Group level was driven by sales growth ahead of market across all divisions. The margin improvement was achieved through productivity improvements which were partially offset by the dilutive effect of ramping up growth projects and a negative mix. Reported EBITDA was impacted by the provision of CHF 285 million for the environmental remediation of the old Gamsenried landfill, with no impact on CORE EBITDA and cash flow. 

Through 2021, Lonza continued to execute its ongoing organic growth projects, as well as confirming new investments. For the Full Year, the total CAPEX reached CHF 1.3 billion or 24% of sales, and it is expected to increase to around 30% in 2022. These investments are focused on delivering the company's long-term investment strategy to capture growth opportunities at attractive margins while minimizing risk. This level of investment was supported by free cash flow, alongside the proceeds from the divestment of Lonza's former Specialty Ingredients business. The company's internal growth investments were accompanied by a selective approach to bolt-on acquisitions. Lonza's new exosomes sites in Lexington (US) and Siena (IT) have expanded its offering in this important emerging area, reflecting its focus on differentiating through innovation.

  • Biologics benefited from continued strong customer demand. The division was able to meet these high demand levels by bringing online and approving new significant expansions across modalities. Compared to Full-Year 2020, the business achieved 24.7%3 sales growth, with a lower CORE EBITDA margin of 36.3%, reflecting a combination of project mix, one-time effects and the impact of growth projects.  
  • Small Molecules saw a significant number of new programs signed and the successful ramp-up of large assets in 2021. The division delivered 11.6%3 sales growth versus Full-Year 2020, alongside a slight margin improvement to 28.0%.  
  • Cell & Gene performance was driven by strong customer demand and improved synergies between the Bioscience business unit and Lonza's CDMO services. As anticipated, the Cell & Gene Technologies business achieved a positive margin in Q4. The wider division saw 26.6%3 sales growth and a margin improvement to 17.6%, compared to Full-Year 2020.  
  • Capsules & Health Ingredients saw solid demand across portfolios and regions. Compared to Full-Year 2020, the division delivered 5.6%3 sales growth, with attractive and improved margins of 34.4%.  
All financial information for financial year 2021 is unaudited. The audit report on the 2021 consolidated financial statements of Lonza Group will be issued in March 2022 together with the publication of Lonza's 2021 Annual Report. For more detail on performance and financials, please refer to the Full-Year 2021 Presentation, Full-Year 2021 Report and Alternative Performance Measures (APM) 2021 Report.

[1] Constant exchange rate

About Lonza Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Lonza Contact Details


End of ad hoc announcement
Language: English
Company: Lonza Group AG
Münchensteinerstrasse 38
4052 Basel
Switzerland
Phone: +4161 316 81 11
Internet: www.lonza.com
ISIN: CH0013841017
Valor: 1384101
Listed: SIX Swiss Exchange
EQS News ID: 1272805
 
End of Announcement EQS News Service

1272805  26-Jan-2022 CET/CEST

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.